Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis.
Brenu, Ekua Weba, Huth, Teilah K, Hardcastle, Sharni L et al. · International immunology · 2014 · DOI
Quick Summary
This study compared immune system cells in 30 people with ME/CFS and 25 healthy controls to identify which immune cells are abnormal in ME/CFS. Researchers found several key differences: patients with ME/CFS had unusual numbers and activity levels of immune cells called B cells, regulatory T cells, and neutrophils. These findings suggest that ME/CFS involves problems with how the immune system regulates itself, similar to autoimmune diseases.
Why It Matters
Understanding which specific immune cells are abnormal in ME/CFS is critical for developing targeted treatments and biomarkers. This study provides detailed cellular fingerprinting that moves beyond general inflammatory markers, potentially enabling future diagnostic tests and mechanistic insights into whether immune dysregulation drives symptoms or is secondary to disease pathology.
Observed Findings
Reduced B-cell subset populations in ME/CFS patients compared to controls
Elevated regulatory T cell (Treg) levels in ME/CFS patients
Decreased cytotoxic NK cell activity and granzyme B production in ME/CFS
Abnormal neutrophil antigen expression in ME/CFS patients
Dysregulated cytokine levels including reduced TNF-α and IFN-γ production
Inferred Conclusions
ME/CFS involves dysregulation of both innate immunity (NK cells, neutrophils) and adaptive immunity (B cells, T cells)
The pattern of immune abnormalities in ME/CFS shares similarities with autoimmune disorders, supporting an autoimmune or immune-dysregulatory mechanism
Impaired immune regulation—rather than simple immune activation—may be central to ME/CFS pathophysiology
Remaining Questions
Do these immune cell abnormalities precede ME/CFS onset or develop after symptom emergence?
How do these cellular changes correlate with symptom severity, duration, or functional impairment in individual patients?
Are the observed immune alterations stable over time or do they fluctuate with disease activity?
What This Study Does Not Prove
This study does not prove that abnormal immune cells cause ME/CFS symptoms—it only documents that differences exist at one point in time. It cannot show whether these immune changes occur before symptom onset, whether they persist or fluctuate over time, or whether correcting them would improve patient outcomes. The small sample size and cross-sectional design limit generalizability.